| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net sales | 811,414 | 894,086 | 895,655 | 666,625 |
| Cost of goods sold | 135,487 | 146,643 | 139,475 | 97,050 |
| Gross profit | 675,927 | 747,443 | 756,180 | 569,575 |
| Selling expenses | 762,548 | 142,253 | 133,954 | 95,430 |
| Research and development | 130,850 | 58,319 | 60,556 | 72,422 |
| General and administrative | 1,882,614 | 2,264,729 | 2,856,768 | 2,052,996 |
| Operating loss | -2,100,085 | -1,717,858 | -2,295,098 | -1,651,273 |
| Amortization of debt discount and issuance cost | - | 0 | - | 40,888 |
| Other expense | - | 0 | - | 8,743 |
| Financing charges | 30,240 | 0 | - | - |
| Interest expense | 29,661 | 13,434 | 2,237 | 64,676 |
| Change in fair value of warrant liability | 1,740 | 119 | -1,831 | 6,726 |
| Other income | 38,930 | 40,993 | 16,820 | 17,072 |
| Total other income (expense), net | -22,711 | 27,440 | 16,414 | -103,961 |
| Net loss | -2,122,796 | -1,690,418 | -2,278,684 | -1,755,234 |
| Preferred stock dividends | 198,707 | 207,465 | 213,543 | - |
| Net loss available to common stockholders | -2,321,503 | -1,897,883 | -2,492,227 | - |
| Basic | 9,878,020 | 8,520,596 | 7,463,578 | 7,172,229 |
| Basic loss per share | -0.24 | -0.22 | -0.33 | -0.25 |
| Diluted | 9,878,020 | 8,520,596 | 7,463,578 | 7,172,229 |
| Diluted loss per share | -0.24 | -0.22 | -0.33 | -0.25 |
Neuraxis, INC (NRXS)
Neuraxis, INC (NRXS)